Bioavailability and related heart function index of digoxin capsules and tablets in cardiac patients

E. Astorri; G. Bianchi; G. la Canna; D. Assanelli; O. Visioli; A. Marzo

Bioavailability and related heart function index of digoxin capsules and tablets in cardiac patients

E. Astorri, G. Bianchi, G. la Canna, D. Assanelli, O. Visioli, A. Marzo

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

A loading dose of digoxin (750 μg) in two commercial formulations was administered to 14 patients with heart disease according to a crossover design. One formulation consisted of soft gelatin capsules containing a solution of digoxin; the other formulation was compressed tablets. All parameters investigated, i.e., serum peak height, time of the peak, area under the serum level-time curve (AUC), and area above the Q-S ₂I (electromechanical systole) decrease (obtained from polycardiographic evaluation), showed better bioavailability of digoxin capsules than tablets, averaging 36.3%. The better bioavailability of digoxin capsules than tablets seems to be more evident in heart disease patients than that encountered previously in healthy subjects. The AUC and the area above the Q-S ₂I decrease were linearly correlated only with digoxin capsules.

Original language	English
Pages (from-to)	104-106
Number of pages	3
Journal	Journal of Pharmaceutical Sciences
Volume	68
Issue number	1
Publication status	Published - 1979

ASJC Scopus subject areas

Drug Discovery
Organic Chemistry
Chemistry(all)
Molecular Medicine
Pharmacology
Pharmaceutical Science

Cite this

@article{9061c14de3bb461c81c3ae228733b498,

title = "Bioavailability and related heart function index of digoxin capsules and tablets in cardiac patients",

abstract = "A loading dose of digoxin (750 μg) in two commercial formulations was administered to 14 patients with heart disease according to a crossover design. One formulation consisted of soft gelatin capsules containing a solution of digoxin; the other formulation was compressed tablets. All parameters investigated, i.e., serum peak height, time of the peak, area under the serum level-time curve (AUC), and area above the Q-S 2I (electromechanical systole) decrease (obtained from polycardiographic evaluation), showed better bioavailability of digoxin capsules than tablets, averaging 36.3%. The better bioavailability of digoxin capsules than tablets seems to be more evident in heart disease patients than that encountered previously in healthy subjects. The AUC and the area above the Q-S 2I decrease were linearly correlated only with digoxin capsules.",

author = "E. Astorri and G. Bianchi and {la Canna}, G. and D. Assanelli and O. Visioli and A. Marzo",

year = "1979",

language = "English",

volume = "68",

pages = "104--106",

journal = "Journal of Pharmaceutical Sciences",

issn = "0022-3549",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Bioavailability and related heart function index of digoxin capsules and tablets in cardiac patients

AU - Astorri, E.

AU - Bianchi, G.

AU - la Canna, G.

AU - Assanelli, D.

AU - Visioli, O.

AU - Marzo, A.

PY - 1979

Y1 - 1979

N2 - A loading dose of digoxin (750 μg) in two commercial formulations was administered to 14 patients with heart disease according to a crossover design. One formulation consisted of soft gelatin capsules containing a solution of digoxin; the other formulation was compressed tablets. All parameters investigated, i.e., serum peak height, time of the peak, area under the serum level-time curve (AUC), and area above the Q-S 2I (electromechanical systole) decrease (obtained from polycardiographic evaluation), showed better bioavailability of digoxin capsules than tablets, averaging 36.3%. The better bioavailability of digoxin capsules than tablets seems to be more evident in heart disease patients than that encountered previously in healthy subjects. The AUC and the area above the Q-S 2I decrease were linearly correlated only with digoxin capsules.

AB - A loading dose of digoxin (750 μg) in two commercial formulations was administered to 14 patients with heart disease according to a crossover design. One formulation consisted of soft gelatin capsules containing a solution of digoxin; the other formulation was compressed tablets. All parameters investigated, i.e., serum peak height, time of the peak, area under the serum level-time curve (AUC), and area above the Q-S 2I (electromechanical systole) decrease (obtained from polycardiographic evaluation), showed better bioavailability of digoxin capsules than tablets, averaging 36.3%. The better bioavailability of digoxin capsules than tablets seems to be more evident in heart disease patients than that encountered previously in healthy subjects. The AUC and the area above the Q-S 2I decrease were linearly correlated only with digoxin capsules.

UR - http://www.scopus.com/inward/record.url?scp=0018345164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018345164&partnerID=8YFLogxK

M3 - Article

C2 - 364006

AN - SCOPUS:0018345164

VL - 68

SP - 104

EP - 106

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 1

ER -

Bioavailability and related heart function index of digoxin capsules and tablets in cardiac patients

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this